Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare. As a significant advancement in the field of antiretroviral therapy, Cabotegravir offers two dosage forms: oral and long-acting injectable, bringing new possibilities for the treatment and prevention of HIV-1 infection in affected individuals.

Indications of Cabotegravir

1. Treatment of HIV-1 Infection

(1) Cabotegravir, when used in combination with EDURANT (Rilpivirine), is indicated for the short-term treatment of HIV-1 infection in adult patients and adolescent patients aged 12 years and older who weigh at least 35 kg.

(2) The specific eligible population must meet the following criteria: virologically suppressed status (HIV-1 RNA < 50 copies/mL).

(3) Currently receiving a stable antiretroviral treatment regimen.

(4) No history of treatment failure.

(5) No known or suspected resistance to Cabotegravir or Rilpivirine.

2. Pre-Exposure Prophylaxis (PrEP) for HIV-1

(1) Cabotegravir is also approved for short-term pre-exposure prophylaxis to reduce the risk of acquiring HIV-1 infection through sexual transmission. It is indicated for adults and adolescents who weigh at least 35 kg. A negative HIV-1 test result must be confirmed before use.

(2) Specific applications include: use as an oral lead-in to assess tolerance to Cabotegravir, in preparation for subsequent use of APRETUDE (Cabotegravir Long-Acting Injectable Suspension).

(3) Use as an oral PrEP medication for patients who may miss scheduled injection doses of APRETUDE.

Dosage Form, Strength and Appearance of Cabotegravir

Dosage Form and Strength

(1) White to off-white film-coated tablets.

(2) Oval, biconvex tablets.

(3) Strength: 30 mg per tablet.

(4) One side of the tablet is engraved with "SVCTV", and the other side is engraved with "30".

Storage Instructions for Cabotegravir

1. Temperature Control

(1) It is recommended to store at 20°C - 25°C.

(2) Short-term storage within the range of 15°C - 30°C is permitted.

2. Humidity Control

(1) Should be kept in the original packaging to prevent moisture exposure.

(2) Keep away from humid environments such as bathrooms.

3. Light Protection

(1) Must be stored away from light to avoid direct sunlight.

(2) It is recommended to keep the tablets in the original aluminum-plastic blister packaging until administration.

4. Safe Storage

(1) Store out of the reach of children and pets.

(2) Do not store in places with large temperature fluctuations, such as the glove compartment of a vehicle.

5. Disposal of Expired Products

(1) Pay attention to checking the expiration date of the medication.

(2) Expired medications should be recycled and disposed of through formal channels.